| | Application No. | A == 1! == == 4/=) | |
|---|---|--|------------------|
| | Application No. | Applicant(s) | |
| Notice of Allowability | 10/659,931 | CHOI ET AL. | |
| | Examiner | Art Unit | |
| | Golam M M Shameem | 1626 | |
| The MAILING DATE of this communication appeared all claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313 | (OR REMAINS) CLOSED in the or other appropriate communication is suf- | nis application. If not included | HIS nitiative |
| 1. \square This communication is responsive to $\underline{9/13/04}$. | | | |
| 2. X The allowed claim(s) is/are 1-6, 8-11, 20-23 and 28-33 (not | <u>w 1-20)</u> . | | |
| 3. The drawings filed on are accepted by the Examiner | . | | |
| 4. ☐ Acknowledgment is made of a claim for foreign priority un a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have | | f). | |
| 2. Certified copies of the priority documents have | | No. | |
| Copies of the certified copies of the priority doc | | | he |
| International Bureau (PCT Rule 17.2(a)). | | and the second s | |
| * Certified copies not received: | | | |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" on noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. | of this communication to file a ENT of this application. | eply complying with the requirements | 3 |
| A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives | tted. Note the attached EXAMI s reason(s) why the oath or de | NER'S AMENDMENT or NOTICE OF claration is deficient. | = |
| $6. \ \square$ CORRECTED DRAWINGS (as "replacement sheets") must | be submitted. | | |
| (a) I including changes required by the Notice of Draftsperson | on's Patent Drawing Review (I | PTO-948) attached | |
| 1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date | - , | • | |
| (b) ☐ including changes required by the attached Examiner's Paper No./Mail Date | Amendment / Comment or in | the Office action of | |
| Identifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the | 34(c)) should be written on the de e header according to 37 CFR 1 | rawings in the front (not the back) of | |
| DEPOSIT OF and/or INFORMATION about the depos attached Examiner's comment regarding REQUIREMENT F | it of BIOLOGICAL MATERI | Al must be submitted. Note the | |
| Attachment(s) | | | |
| I. ☐ Notice of References Cited (PTO-892) | 5. Notice of Inform | nal Patent Application (PTO-152) | |
| 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) | 6. Interview Summ | nary (PTO-413). | |
| Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date | Paper No./Mai), 7. ☐ Examiner's Am | I Date endment/Comment | |
| . ☐ Examiner's Comment Regarding Requirement for Deposit | 8. 🛛 Examiner's Sta | ement of Reasons for Allowance | |
| of Biological Material | 9. 🗌 Other | · | |
| | | | |
| | | | |
| | | | |
| | | |] |

Application/Control Number: 10/659,931

Art Unit: 1626

DETAILED ACTION

Status of Claims

Claims 1-6, 8-11, 20-23 and 28-33 are pending in the application.

Receipt is acknowledged of Applicant's amendment / response filed on September 13, 2004 and that has been entered.

Claims 1 and 20 have been amended. Claims 7, 12-19 and 24-27 have been canceled.

The objection of claims 1-6, 8-11, 28 and 29 has been obviated with Applicant's amendment. Claims 20-23 and 30-33 have been rejoined because those claims fall within the scope of the elected invention. Therefore, the restriction requirement between the compounds and methods of uses has been withdrawn and all pending claims have been allowed.

Reasons for allowance

The following is an Examiner's statement of reasons for allowance:

Berger *et al* (US 5,688,830) teach a compound of the Formula I, which is useful as sodium channel blockers, and are particularly useful for the alleviation of neuropathic pain. The instant compound differs from the prior art by having a compound of the formula (I), which is further substituted by different variables such as R₇, R₈, and A₂₀ etc that are attached directly or indirectly to the core heterocyclic ring and are useful for treating a disease or condition associated with sodium channel activity. The prior art compound neither teaches nor renders obvious the instant claimed invention and there is no suggestion or motivation to modify the compound of other prior art to obtain the instant compounds. Therefore, the instant claims 1-6, 8-11, 20-23 and 28-33 are allowable over the prior art of record.

Application/Control Number: 10/659,931

Art Unit: 1626

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (571) 272-0699. The Unofficial fax phone number for this Group is (703) 308-7922. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.

Page 4

Golam M M Shameem, Ph.D. Patent Examiner Art Unit 1626, Group 1620 Technology Center 1

November 5, 2004